Description: Pharma Mar, S.A., a biopharmaceutical company, engages in the discovery and development of marine-derived anticancer drugs in Spain and internationally. The company operates through two segments, Biopharmaceuticals and Consumer Chemicals. It develops and commercializes Yondelis, an antitumor agent for the treatment of advanced soft tissue sarcomas and for relapsed ovarian cancer. The company also develops clinical-stage programs, including Aplidin, Lurbinectedin, PM184, and PM14. In addition, it develops and provides diagnostics kit for genetic diagnostics and DNA analysis; and produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Pharma Mar, S.A. was founded in 1986 and is based in Madrid, Spain.
Home Page: www.pharmamar.com
Avenida de los Reyes, 1
Madrid,
28770
Spain
Phone:
34 91 846 60 00
Officers
| Name | Title |
|---|---|
| Mr. Jose Maria Fernandez Sousa-Faro | Founder, Exec. Chairman, CEO & Pres |
| Mr. Pedro Francisco Fernandez Puentes | Exec. Vice-Chairman |
| Mr. Juan Carlos-Torres Carretero | Founder |
| Ms. María Luisa de Francia Caballero | Chief Financial Officer |
| Ms. Elena Calleja Crespo | Director of Fin. & Admin. |
| Mr. José Luis Moreno Martinez-Losa | Director of Capital Markets & Investor Relations |
| Mr. Juan Gomez Pulido | Gen. Counsel & Sec. of the Board of Directors |
| Ms. Sandra Llamera Sanchez | Global Compliance Head |
| Ms. Lara Vadillo | Communication Director |
| Mr. Juan Nogues | Director of International Marketing & Sales |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 13.9228 |
| Price-to-Book MRQ: | 5.6047 |
| Price-to-Sales TTM: | 5.5667 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 477 |